Influence of lipid composition and drug load on the In Vitro performance of self-nanoemulsifying drug delivery systems

Journal of Pharmaceutical Sciences

Volumn 101, Issue 5, 2012, Pages 1721-1731

  Thomas, Nicky ^a   Müllertz, Anette ^b   Graf, Anja ^a   Rades, Thomas ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Dispersion; Drug load; in vitro models; Lipid chain length; Lipids; Oral drug delivery; Precipitation; Self nanoemulsiying drug delivery system (SNEDDS)

Indexed keywords

CREMOPHOR; LIPID; SIMVASTATIN; SURFACTANT;

ARTICLE; DISPERSION; DRUG DELIVERY SYSTEM; IN VITRO STUDY; LIPID COMPOSITION; LIPOLYSIS; NANOEMULSION; PRECIPITATION; CHEMISTRY; EMULSION; NANOTECHNOLOGY;

DRUG DELIVERY SYSTEMS; EMULSIONS; LIPIDS; NANOTECHNOLOGY;

EID: 84864323714     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23054     Document Type: Article

References (40)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23(1-3):3-25.
2. Amidon G, Lennernaes H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutics drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413-420.
3. Gershanik T, Benita S. 2000. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 50(1):179-188.
4. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennerns H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2003. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1(1):85-96.
5. Chakraborty S, Shukla D, Mishra B, Singh S. 2009. Lipid-An emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 73(1):1-70.
6. Hauss DH. 2007. Oral lipid-based formulations. Adv Drug Deliv Rev 59(7):667-676.
7. Müllertz A, Ogbonna A, Ren S, Rades T. 2010. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 62:1622-1636.
8. Porter CJH, Pouton CW, Cuine JF, Charman WN. 2008. Enhancing intenstinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev 60(6):673-691.
9. Strickley RG. 2004. Solubilizing excipients in oral and injectable formulations. Pharm Res 21(2):201-230.
10. Drewe J, Meier R, Vonderscher J, Kiss D, Posanski U, Kissel T, Gyr K. 1992. Enhancement of the oral absorption of cyclosporin in man. Br J Clin Pharmacol 34(1):60-64.
11. Fatouros DG, Karpf DM, Nielsen FS, Müllertz A. 2007. Clinical studies with oral lipid based formulations of poorly soluble compounds. Ther Clin Risk Manag 3(4):591-604.
12. Kovarik JM, Mueller EA, Van Bree JB, Tetzloff W, Kutz K. 1994. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 83(3):444-446.
13. Mueller EA, Kovarik JM, van Bree JB, Grevel J, Lücker PW, Kutz K. 1994. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 11(1):151-155.
14. Ali MH, Kirby DJ, Mohammed AR, Perrie Y. 2010. Solubilisation of drugs within liposomal bilayers: Alternatives to cholesterol as a membrane stabilising agent. J Pharm Pharmacol 62(11):1646-1655.
15. Porter CJH, Trevaskis NL, Charman WN. 2007. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6:231-248.
16. Kossena GA, Charman WN, Boyd BJ, Porter CJH. 2005. Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug. J Pharm Sci 94(3):481-492.
17. Carey MC, Staggers JE, Hernell O, Stafford RJ. 1990. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 1. Phase behavior and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. Biochemistry (Mosc) 29(8):2028-2040.
18. Carey MC. 1990. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry (Mosc) 29(8):2041-2056.
19. Porter CJH, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN. 2004. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res 21(8):1405-1412.
20. Grove M, Müllertz A, Nielsen JL, Pedersen GP. 2006. Bioavailability of seocalcitol II: Development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Eur J Pharm Sci 28(3):233-242.
21. Mohsin K, Long MA, Pouton CW. 2009. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: Precipitation of drug after dispersion of formulations in aqueous solution. J Pharm Sci 98(10):1-14.
22. Kaukonen AM, Boyd BJ, Porter CJH, Charman WN. 2004. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations. Pharm Res 21(2):245-253.
23. Cuiné JF, Claire L, McEvoy CL, Charman WN, Pouton CW, Edwards GA, Benameur H, Porter CJH. 2008. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J Pharm Sci 97(2):995-1012.
24. Pouton CW. 2000. Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci 11(Suppl 2):S93-S98.
25. Pouton CW. 2006. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 29(3-4):278-287.
26. Zangenberg NH, Müllertz A, Kristensen HG, Hovgaard L. 2001. A dynamic in vitro lipolysis model: I. Controlling the rate of lipolysis by continuous addition of calcium. Eur J Pharm Sci 14(2):115-122.
27. Sassene PJ, Knopp MM, Hesselkilde JZ, Koradia V, Larsen A, Rades T, Müllertz A. 2010. Precipitation of a poorly soluble model drug during in vitro lipolysis: Characterization and dissolution of the precipitate. J Pharm Sci 99(12):4982-4991.
28. Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G, Lee HB, Cho SH. 2004. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 274(1-2):65-73.
29. Christensen J, Schultz K, Mollgard B, Kristensen HG, Müllertz A. 2004. Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. Eur J Pharm Sci 23(3):287-296.
30. Khoo S-M, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. 1998. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm 167(1-2):155-164.
31. Deckelbaum RJ, Hamilton JA, Moser A, Bengtsson-Olivecrona G, Butbul E, Carpentier YA, Gutman A, Olivecrona T. 1990. Medium-chain vs long-chain triacylglycerol emulsion hydrolysis by lipoprotein lipase and hepatic lipase: Implications for the mechanisms of lipase action. Biochemistry (Mosc) 29(5):1136-1142.
32. Porter CJH, Kaukonen AM. 2004. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Studies with halofantrine. J Pharm Sci 93(5):1110-1121.
33. Sek L, Pouton CW, Kaukonen AM, Charman WN. 2002. Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. J Pharm Pharmacol 54(1):29-41.
34. Reis P, Holmberg K, Watzke H, Leser ME, Miller R. 2009. Lipases at interfaces: A review. Adv Colloid Interface Sci 147-148:237-250.
35. Cuiné JF, Charman WN, Pouton CW, Edwards GA, Porter CJH. 2004. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs. Pharm Res 24(4):748-757.
36. Christiansen A, Backensfeld T, Weitschies W. 2010. Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes. Eur J Pharm Sci 41(2):376-382.
37. Fatouros DG, Deen GR, Arleth L, Bergenstahl B, Nielsen FS, Pedersen JS, Mullertz A. 2007. Structural development of self nano emulsifying drug delivery systems (SNEDDS) during in vitro lipid digestion monitored by small-angle X-ray scattering. Pharm Res 24(10):1844-1853.
38. Larsen A, Holm R, Pedersen M, Müllertz A. 2008. Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: In vivo bioavailability and dynamic in vitro lipolysis. Pharm Res 25(12):2769-2777.
39. Boyd BJ, Porter CJH, Charman WN. 2003. Using the polymer partitioning method to probe the thermodynamic activity of poorly water-soluble drugs solubilized in model lipid digestion products. J Pharm Sci 92(6):1262-1271.
40. Charman WN, Porter CJH, Mithani S, Dressman JB. 1997. Physicochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharm Sci 86(3):269-282.